News

There are many reasons to invest in excellent dividend stocks. Such investments are often worth the trouble regardless of whether you're investing for the dividend, or for making capital gains from

It's been more than a year since AbbVie (NYSE: ABBV) lost patent exclusivity for its most important product, Humira, an immunology medicine. Though this was a long time coming, the market reacted as

Don't believe the adage to "sell in May and go away." Buying stocks can still be a smart move, especially if you're a long-term investor.

Three Motley Fool contributors have identified stocks they

Weight loss translates to investor profits. Just look at Eli Lilly and Novo Nordisk. Both stocks have skyrocketed thanks largely to their obesity drugs, with Lilly's share price more than

Amgen (NASDAQ: AMGN) released its latest set of quarterly results after market hours Thursday, and investors rewarded the pharmaceutical company the following day with a lift to its share price. The

Image source: The Motley Fool.

Zoetis (NYSE: ZTS)Q1 2024 Earnings CallMay 02, 2024, 8:30 a.m. ET

Operator

Continue reading

Source Fool.com

Image source: The Motley Fool.

Geron (NASDAQ: GERN)Q1 2024 Earnings CallMay 02, 2024, 8:00 a.m. ET

Operator

Continue reading

Source Fool.com

Investors were meowing for animal healthcare specialist Zoetis (NYSE: ZTS) on Thursday, following the company's release of its latest quarterly results. These obviously pleased market participants

The phrase "the golden age of biotech" was somewhat popular a few years ago but now seems largely forgotten. Regardless, biotech companies can be excellent long-term investment options for several

Many investors consider Nvidia (NASDAQ: NVDA) the ultimate artificial intelligence (AI) stock for two solid reasons: The company dominates the AI chip market and has turned this leadership into

Pfizer (NYSE: PFE) stock is an investing enigma. The drugmaker's shares have printed fresh 52-week lows consistently over the past two years, putting its stock in serious bargain territory. Speaking

AT&T (NYSE: T) stock has struggled in recent years, but Barclays analyst Kannan Venkateshwar believes the company deserves a higher valuation, considering the recent subscriber gains for its

Image source: The Motley Fool.

Sarepta Therapeutics (NASDAQ: SRPT)Q1 2024 Earnings CallMay 01, 2024, 4:30 p.m. ET

Operator

Continue reading

Source Fool.com

Image source: The Motley Fool.

Pfizer (NYSE: PFE)Q1 2024 Earnings CallMay 01, 2024, 10:00 a.m. ET

Operator

Continue reading

Source Fool.com

Pfizer (NYSE: PFE) stock got a very effective shot in the arm on Wednesday. This was supplied by its latest earnings release, which saw the storied pharmaceutical company notch double beats on

Image source: The Motley Fool.

Amarin Plc (NASDAQ: AMRN)Q1 2024 Earnings CallMay 01, 2024, 8:00 a.m. ET

Operator

Continue reading

Source Fool.com

A lot will change in the next 10 years, but our need for innovative medicines is unlikely to be one of them. That's one thing that makes some biotech companies exciting long-term investment

Image source: The Motley Fool.

Exelixis (NASDAQ: EXEL)Q1 2024 Earnings CallApr 30, 2024, 5:00 p.m. ET

Operator

Continue reading

Source Fool.com

Earnings season is officially here. As per usual, there have already been epic sell-offs and run-ups across well-known names.

However, long-term investors know that the best way to view a quarterly

So far, 2024 has been a year to forget for animal healthcare juggernaut Zoetis (NYSE: ZTS). Hit by the triple whammy of weak earnings, a formal investigation from the European Commission, and

I owned shares of Pfizer (NYSE: PFE) when the COVID-19 pandemic started. Watching the stock soar over 60% in roughly two years was fun. Seeing Pfizer's share price fall nearly 60% from its peak

The market isn't rational always and everywhere. Sometimes, shares of excellent companies with bright futures almost inexplicably fail to keep pace with broader equities. When that happens, it's